Psoriasis News and Research

Latest Psoriasis News and Research

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, today announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.

7 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

Research: Tanning bed exposure can lead to serious skin problems

Tanning bed exposure can produce more than some tanners may bargain for, especially when they self-diagnose and use the radiation to treat skin eruptions, according to research conducted by the Indiana University School of Medicine Department of Dermatology.

2 Mar 2011

LEO selects Veeva CRM to support its rapidly growing New Markets Europe region

LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, has selected Veeva CRM to support its rapidly growing New Markets Europe region. LEO has started the deployment of Veeva CRM to its users in countries such as Hungary, Czech Republic, Slovakia, Poland, Romania, and Italy.

1 Mar 2011

American Academy of Dermatology releases final guidelines of care for psoriasis

Building on the evidence-based findings of five previously published guidelines of care that examine the use of a variety of medical therapies for the management and treatment of psoriasis and psoriatic arthritis, the American Academy of Dermatology has released its sixth and final guidelines of care for psoriasis.

16 Feb 2011

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Idera Pharmaceuticals, Inc. announced today that it is presenting data on IMO-3100, an antagonist of TLR7 and TLR9, in a preclinical model of lupus showing that treatment with IMO-3100 suppressed several key disease progression parameters.

15 Feb 2011

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Anacor Pharmaceuticals, Inc. and Medicis Pharmaceutical Corporation today announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

11 Feb 2011

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.

9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

NMS Labs launches unique test for Methotrexate

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.

8 Feb 2011

Researchers identify immune cell population that acts as body's border patrol with the outside world

So-called barrier sites -- the skin, gut, lung - limit the inner body's exposure to allergens, pollutants, viruses, bacteria, and parasites. Understanding how the immune system works in these external surfaces has implications for understanding such inflammatory diseases as asthma, psoriasis, IBD, and food allergies, all of which occur at the body's barriers.

8 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

4 Feb 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Isotechnika Pharma Inc. is pleased to announce that it has finalized the Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd., previously announced on November 16, 2010. Isotechnika will now receive the license fee of US$4.5 million plus proceeds of US$2.375 million from ILJIN's purchase of its first tranche of Common Shares from treasury.

3 Feb 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Ben-Gurion University of the Negev and the PTT Chemical Public Company Ltd. in Thailand have signed a research and development collaboration agreement for commercial development of BGU's proprietary green algae strain.

29 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.

27 Jan 2011

DMP1 protein prevents endothelial cells to respond to VEGF

A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.

27 Jan 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.

27 Jan 2011

Psoriasis News and Research

Latest Psoriasis News and Research

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Research: Tanning bed exposure can lead to serious skin problems

LEO selects Veeva CRM to support its rapidly growing New Markets Europe region

American Academy of Dermatology releases final guidelines of care for psoriasis

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

NMS Labs launches unique test for Methotrexate

Researchers identify immune cell population that acts as body's border patrol with the outside world

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

DMP1 protein prevents endothelial cells to respond to VEGF

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in